Literature DB >> 22391960

Incidence and clinical predictors of low defibrillation safety margin at time of implantable defibrillator implantation.

Zhongwei Cheng1, Mintu Turakhia, Ronald Lo, Anurag Gupta, Paul C Zei, Henry H Hsia, Amin Al-Ahmad, Paul J Wang.   

Abstract

BACKGROUND: Determination of the defibrillation safety margin (DSM) is the most common method of testing device effectiveness at the time of implantation of implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRTD). Low DSM remains a problem in clinical practice.
OBJECTIVE: The purpose of this study is to ascertain the incidence and clinical predictors of low DSM and the treatment strategies for low DSM in ICD or CRTD recipients.
METHODS: Selected ICD or CRTD recipients from January 2006 to May 2008 who underwent DSM test at the time of implantation were included. Low DSM patients were defined as patients who had a DSM within 10 J of the maximum delivered energy of the device. These patients were compared to patients who had DSM > 10 J.
RESULTS: This study included 243 patients. Of these, 13 (5.3%) patients had low DSM, and 230 patients had adequate DSM. Patients with low DSM had a high prevalence of amiodarone use (69% vs 13%, p < 0.01), secondary prevention indications (69% vs 30%, p < 0.01), and a trend toward younger age (51 ± 18 vs 58 ± 15 years, p = 0.08). After adjustment for age and sex, amiodarone use was significantly associated with low DSM. All low DSM patients except one obtained adequate DSM after taking additional steps, including discontinuing amiodarone and starting sotalol, RV lead repositioning, adding a subcutaneous array or shock coil, changing single-coil to dual-coil lead, and upgrading to a high output device.
CONCLUSION: The incidence of low DSM patients is low with high-energy devices. Amiodarone use is associated with low DSM, and its discontinuation or substitution with sotalol is one of a variety of available options for low DSM patients.

Entities:  

Mesh:

Year:  2012        PMID: 22391960     DOI: 10.1007/s10840-011-9648-z

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  57 in total

1.  Passive electrode effect reduces defibrillation threshold in bi-filament middle cardiac vein defibrillation.

Authors:  John R Paisey; Arthur M Yue; Frederick Bessoule; Paul R Roberts; John M Morgan
Journal:  Europace       Date:  2006-01-11       Impact factor: 5.214

2.  Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.

Authors:  Stefan H Hohnloser; Paul Dorian; Robin Roberts; Michael Gent; Carsten W Israel; Eric Fain; Jean Champagne; Stuart J Connolly
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

3.  Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements.

Authors:  E G Daoud; K C Man; L Horwood; F Morady; S A Strickberger
Journal:  Am J Cardiol       Date:  1997-01-01       Impact factor: 2.778

4.  DL and D sotalol decrease defibrillation energy requirements.

Authors:  M Wang; P Dorian
Journal:  Pacing Clin Electrophysiol       Date:  1989-09       Impact factor: 1.976

5.  Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?

Authors:  Andrea M Russo; William Sauer; Edward P Gerstenfeld; Henry H Hsia; David Lin; Joshua M Cooper; Sanjay Dixit; Ralph J Verdino; Hemal M Nayak; David J Callans; Vickas Patel; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2005-05       Impact factor: 6.343

6.  High defibrillation threshold at cardioverter defibrillator implantation under amiodarone treatment: favorable effects of D, L-sotalol.

Authors:  G Boriani; M Biffi; L Frabetti; M Maraschi; A Branzi
Journal:  Heart Lung       Date:  2000 Nov-Dec       Impact factor: 2.210

7.  A subcutaneous lead array for implantable cardioverter defibrillators.

Authors:  L Jordaens; P Vertongen; Y van Belleghem
Journal:  Pacing Clin Electrophysiol       Date:  1993-07       Impact factor: 1.976

8.  Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold.

Authors:  L Zhou; B P Chen; J Kluger; C Fan; M S Chow
Journal:  J Am Coll Cardiol       Date:  1998-06       Impact factor: 24.094

9.  Clinical characteristics and outcome of patients with high defibrillation thresholds. A multicenter study.

Authors:  A E Epstein; K A Ellenbogen; K A Kirk; G N Kay; S M Dailey; V J Plumb
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

10.  Complications associated with defibrillation threshold testing: the Canadian experience.

Authors:  David Birnie; Stanley Tung; Christopher Simpson; Eugene Crystal; Derek Exner; Felix-Alejandro Ayala Paredes; Andrew Krahn; Ratika Parkash; Yaariv Khaykin; Francois Philippon; Peter Guerra; Shane Kimber; Douglas Cameron; Jeffrey S Healey
Journal:  Heart Rhythm       Date:  2007-11-28       Impact factor: 6.343

View more
  2 in total

1.  Anti-arrhythmics in out-of-hospital cardiac arrest: lessons from a randomized controlled trial.

Authors:  Yann-Laurent Violin; Clément Derkenne; Daniel Jost; Jean-Pierre Tourtier
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

2.  How to Manage a High Defibrillation Threshold in ICD Patients: and Does it Really Matter?

Authors:  Maria Vittoria Matassini; Jeff S Healey
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.